Test Description

Mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) immunohistochemistry is a collective qualitative assay to identify patients eligible for treatment with JEMPERLI® (dostarlimab-gxly) or KEYTRUDA® (pembrolizumab) in MMR deficient (dMMR) solid tumours including endometrial carcinoma, and a combination of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib) in MMR proficient (pMMR) endometrial carcinoma. 


Therapy and associated indication:



Ordering Information

Test Code: MMR




Genes: MLH1, PMS2, MSH2, MSH6


Turnaround Time: 3 - 5 working days, upon sample receipt


Accepted Specimens: 

  • FFPE Tissue/Cell Blocks
  • FFPE Slides


Refer to Specimen Requirements for more information.